The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor

British Journal of Cancer

Volumn 76, Issue 7, 1997, Pages 946-951

  Gerrits, C J H ^a   Schellens, J H M ^a   Creemers, G J ^a   Wissel, P ^b   Planting, A S Th ^a   Pritchard, J F ^b   DePee, S ^b   De Boer Dennert, M ^a   Harteveld, M ^a   Verweij, J ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Bioavailability; GI147211 (GG211); Phase I study; Topoisomerase I inhibitor

Indexed keywords

CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE INHIBITOR; LURTOTECAN;

ANEMIA; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TOLERABILITY; FEEDING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SOLID TUMOR; STOMACH PAIN; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 9844250206     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.490     Document Type: Article

References (41)

1. Aller P, Rius C, Mata F, Zorilla A, Carbanas C, Bellon T and Bernabeu C (1992) Camptothecin induces differentiation and stimulates the expression of differentiation-related genes in U-937 human promonocytic leukemia cells. Cancer Res 52: 1245-1251
2. Andoh T, Ishii K, Suzuki Y, Ikegami Y, Kusunoki Y, Takemoto Y and Okada K (1987) Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 84: 5565-5569
3. Bendixen C, Thomsen B, Alsner J and Westergaard O (1990) Camptothecin-stabilized topoisomerase I-DNA adducts cause premature termination of transcription. Biochemistry 12: 5613-5619
4. Camilloni G, Di Martino E and Di Mauro E (1989) Regulation of the function of eukaryotic DNA topoisomerase I: topological conditions for inactivity. Proc Natl Acad Sci USA 86: 308-3084
5. Champoux J (1976) Evidence from an intermediate with a single strand break in the reaction catalyzed by the DNA untwisting enzyme. Proc Natl Acad Sci USA 73: 3488-3491
6. Creaven PJ, Allen LM and Muggia FM (1972) Plasma camptothecin (NSC 100880) levels during a 5-day course of treatment: relation to dose and toxicity. Cancer Chem Rep 56: 573-578
7. Creemers GJ, Lund B and Verweij J (1994) Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev 20: 73-96
8. Creemers GJ, Gerrits CJH, Schellens JHM, Planting AST, Van Der Burg MEL, Van Beurden V, De Boer-Dennert M, Harteveld M, Loos W, Hudson I, Stoter G and Verweij JJ (1996) Phase II and pharmacologic study on topotecan administered as a 21-days continuous infusion to patients with colorectal cancer. J Clin Oncl 9: 2540-2545
9. Emerson DL, Vuong A, McIntyre MS, Croom D and Besterman JM (1993) In vivo efficacy of two new water-soluble camptothecin analogs in the human cancer xenograft model. Proc Am Assoc Cancer Res 34: 419
10. Emerson DL, Besterman JM, Braun R, Evans MG, Leitner PP, Luzzio MJ, Shaffer JE, Sternbach DD, Uehling D and Vuong A (1995) In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues. Cancer Res 55: 603-609
11. Eng WK, McCabe FL, Tan KB, Mattorn MR, Hofmann GA, Woessner RP, Hertzberg RP and Johnson RK (1990) Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol 38: 471-180
12. Gerrits CJH, Creemers GJ, Schellens JHM, Wissel PS, Planting AST, Kunka R, Selinger K, De Boer-Dennert M, Marijnen Y, Harteveld M and Verweij J (1996) Phase I and pharmacologic study of the new topoisomerase I inhibitor GI147211, using a daily ×5 intravenous administration. Br J Cancer 73: 744-750
13. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R and Potmesil M (1989) DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046-1048
14. Gottlieb JA, Guarino AM, Call JB, Oliverio VT and Block JB (1970) Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chem Rep 54: 461-470
15. Gupta RS, Gupta R, Eng B, Lock RB, Ross WE, Hertzberg RP, Caramfam J and Johnson RK (1988) Camptothecin-resistant mutants of Chinese hamster ovarian cells containing a resistant form of topoisomerase I. Cancer Res 48: 6404-6410
16. Hirabajashi N, Kim R, Nishiyama M, Aogi K, Saeki S, Toge T and Okada K (1992) Tissue expression of topoisomerase I and II in digestive tract cancers and adjacent normal tissues. Proc Am Assoc Cancer Res 33: 436
17. Hochster H, Liebes L, Speyer J, Gorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ and Blum RH (1994) Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 12: 553-559
18. Houghton PJ, Chesine PJ, Hallman JD, Lutz L, Friedman HS, Danks MK and Houghton JA (1995) Efficacy of topoisomerase I inhibitors, topotecan and irinotecan administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36: 393-403
19. Hsiang YH and Liu LF (1988) Identification of mammalian DNA topoisomerase I as an intra cellular target of the anticancer drug camptothecin. Cancer Res 48: 1722-1726
20. Hsiang YH, Hertzberg R, Hecht S and Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873-14878
21. Kaufmann WK, Boyer JC, Estabrooks LL and Wilson SJ (1991) Inhibition of replicon initiation in human cells following stabilization of topoisomerase-DNA cleavable complexes. Mol Cell Biol 11: 3711-3718
22. Kharbanda S, Rubin E, Gunji, Hinz H, Giovanella B, Pantazis P and Dufe D (1991) Camptothecin and its derivatives induce expression of the c-jun-protooncogene in human myeloid leukemia cells. Cancer Res 51: 6636-6642
23. Kuhn J, Rizzo J, Eckhardt J, Fields S, Cobb P, Rodriguez G, Rinaldi D, Drengler R, Smith L, Peacock, Thurman A, De La Cruz P, Hodges S, Von Hoff D and Burris H (1995) Phase I bioavailability study of oral topotecan (abstract 1538). Proc Am Assoc Clin Oncol 14: 474
24. Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351-375
25. Muggia FM, Creaven PJ, Hansen HH, Cohen MH and Selanrig OS (1972) Phase I clinical trial of weekly and daily treatment with camptothecin (NSC 100880): correlation with preclinical studies. Cancer Chem Rep 56: 515-521
26. Muller M (1985) Quantitation of eukaryotic topoisomerase I reactivity with DNA. Preferential cleavage of supercoiled DNA. Biochim Biophys Acta 824: 263-267
27. Muller M, Pfund W and Mehta V (1985) Eukaryotic type I topoisomerase is enriched in the nucleolus and catalytically active on ribosomal DNA. EMBO J 4: 1237-1243
28. Nakaya K, Chou S, Kaneko M and Nakamura Y (1991) Topoisomerase inhibitors have potent differentiation-inducing activity for human and mouse myeloid leukemia cells. Jpn J Cancer Res 82: 184-191
29. National Cancer Institute (1988) Guidelines for Reporting of Adverse Drug Reactions. Division of Cancer Treatment, National Cancer Institute: Bethesda, MD, USA
30. Potmesil M (1994) Camptothecins: from bench research to hospital wards. Cancer Rev 54: 1431-1439
31. Potmesil M, Hsiang YH, Liu LF, Bank B, Grossberg M, Kirschenbaum S, Forlenza TJ, Penziner A, Kanganis D, Knowles D, Traganos F, and Silber R (1988) Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase I. Cancer Res 48: 35380-3543
32. Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Horowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kauf-Mann SH and Donehower RC (1992) Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 10: 647-656
33. Schellens JHM, Creemers GJ, Beijnen JH, Rosing H, McDonald M, Davies B and Verweij J (1996) Bioavailability and pharmacokinetics of oral topotecan, a new topoisomerase I inhibitor. Br J Cancer 73: 1268-1271
34. Slichenmyer WJ, Rowinsky EK, Donehower RC and Kaufmann SH (1993) The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85: 271-291
35. Stafford CG and St Claire III RL (1995) High-performance liquid chromatographic analysis of the lactone and carboxylate forms of a topoisomerase I inhibitor (the antitumor drug GI147211) in plasma. J Chromatogr 663: 119-126
36. Sugimoto Y, Tsukahara S, Oh-Hara T, Isoe T and Tsurno T (1990) Decreased expression of topoisomerase I in camptothecin-resistant tumor cell lines as determined by monoclonal antibody. Cancer Res 50: 6925-6930
37. Tanizawa A and Pommier Y (1992) Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. Cancer Res 52: 1848-1854
38. Verschraegen CF, Natelson E, Giovanella B, Kavanagh JJ, Freed Man RS, Kudalka AP, Edwards CL and Stehlin J (1986) Phase I study of oral 9-Nitrocamptothecin (9NC). Proc Am Soc Clin Oncol 15: 482
39. Verweij J, Lund B, Beijnen J, Planting A, De Boer-Dennert M, Koier I, Rosing H and Hansen H (1993) Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 4: 673-678
40. World Health Organization (1979) WHO Handbook for Reporting Results of Cancer Treatment (1979). WHO Offset Publication no. 40: Geneva. Switzerland
41. Wyllie AH and Duvall E (1992) Cell injury and death. In Oxford Textbook of Pathology: Principles of Pathology Vol 1, McGee O'D, Isaacson PG and Wright NA. (eds), pp. 141-157, Oxford University Press: New York